BioWorld - Tuesday, April 21, 2026

BioWorld Science

Aug. 27, 2021

View Archived Issues

Phase I study evaluates PGV-001-based personalized multipeptide vaccines for prostate cancer

Read More

Phase I trial of molecular targeted therapy with adoptive cell therapy for DIPG and neuroblastoma

Read More

XRad initiates phase Ia study of XRD-0394 with radiation therapy in advanced solid tumors

Read More

Foghorn Therapeutics discovers SMARCA2/SMARCA4 inhibitors

Read More

Cannabinoid CB1/CB2 receptor partial agonists patented by Research Triangle Institute

Read More

BioTheryX presents PROTACs including casein kinase I isoform alpha degradation inducers

Read More

Stressed fat cells send mitochondria to teach heart cells self-defense

Read More

Landos collaborates with Johns Hopkins to further validate NLRX1 immunometabolic pathway in MS

Read More

MKK-4 inhibition for liver regeneration

Read More

Airway initiates phase Ib trial of AT-100 in mechanically ventilated patients with COVID-19

Read More

Chinese clearance for phase Ib/III trial of afuresertib with fulvestrant in HR+, HER- breast cancer

Read More

Pardes initiates phase I study of antiviral PBI-0451 for SARS-CoV-2 infection

Read More

Unnatural Products targets MDM2 and MDM4 with macrocylic peptides

Read More

Data presented for Sage Therapeutics' SAGE-718 for neurological diseases

Read More

First-in-human study planned with NXP-800 in advanced cancers

Read More

Preclinical studies characterize bispecific EGFR/CD16A NK innate cell engager AFM-24

Read More

RubrYc enters license and collaboration agreements on epitope-targeted antibody therapeutics

Read More